KPC-12 is a variant of KPC-2 with a L169M substitution in the Ω loop, but its resistance spectrum was not reported. bla was cloned, and KPC-12 exhibited significantly decreased activities against imipenem, meropenem, aztreonam, and piperacillin-tazobactam with ≥4-fold lower MICs than KPC-2. However, unlike the L169P substitution in KPC-35, activities against ceftazidime and ceftazidime-avibactam of KPC-12 were unaltered. This highlights that different substitutions at the same position of carbapenemases may have varied impact on the activity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10096-021-04198-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical emergence of a novel extended-spectrum variant deriving from the OXY-1 β-lactamase.
Eur J Clin Microbiol Infect Dis
November 2024
Service de Bactériologie, Assistance Publique Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Site Cochin, 27 rue du Faubourg Saint-Jacques, Paris, 75014, France.
Article Synopsis
- Two clinical isolates of Klebsiella michiganensis from the same patient were genetically compared, revealing differing resistance profiles: one was resistant to piperacillin-tazobactam and intermediate to cefotaxime, while the other was resistant to ceftazidime but susceptible to piperacillin-tazobactam.
- * A mutation in the bla gene, resulting in a L169M change in the Ω loop, was identified as a key factor in the resistance differences.
- * Cloning experiments in E. coli demonstrated that this mutation allowed for increased resistance to ceftazidime and cefepime but reduced resistance to piperacillin-tazobactam, marking a novel discovery of how
KPC-12 with a L169M substitution in the Ω loop has reduced carbapenemase activity.
Eur J Clin Microbiol Infect Dis
August 2021
Center of Infectious Diseases, West China Hospital, Sichuan University, Guoxuexiang 37, Chengdu, 610041, Sichuan, China.
KPC-12 is a variant of KPC-2 with a L169M substitution in the Ω loop, but its resistance spectrum was not reported. bla was cloned, and KPC-12 exhibited significantly decreased activities against imipenem, meropenem, aztreonam, and piperacillin-tazobactam with ≥4-fold lower MICs than KPC-2. However, unlike the L169P substitution in KPC-35, activities against ceftazidime and ceftazidime-avibactam of KPC-12 were unaltered.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!